Silexion Therapeutics Announces Warrant Exercise Agreement
Ticker: SLXNW · Form: 8-K · Filed: Dec 16, 2024 · CIK: 2022416
Sentiment: neutral
Topics: warrants, capital-raising, disclosure
Related Tickers: SLXN
TL;DR
Silexion Therapeutics (SLXN) warrants exercisable at $1.150/share.
AI Summary
Silexion Therapeutics Corp. announced on December 16, 2024, that it has entered into a warrant exercise agreement. This agreement allows for the exercise of warrants at an exercise price of $1.150 per share. The company's former name was Biomotion Sciences, with the name change effective May 6, 2024.
Why It Matters
This filing indicates potential new capital inflow for Silexion Therapeutics as warrants are exercised, which could impact its financial position and operational capacity.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a warrant exercise agreement and does not present immediate financial or operational risks.
Key Numbers
- $1.150 — Warrant Exercise Price (Price per share for warrant exercise)
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- December 16, 2024 (date) — Report date
- December 10, 2024 (date) — Earliest event reported
- May 6, 2024 (date) — Date of name change
- $1.150 (dollar_amount) — Warrant exercise price
FAQ
What is the total number of warrants that can be exercised under this agreement?
The filing does not specify the total number of warrants available for exercise, only the exercise price.
When is the expiration date for these warrants?
The filing does not mention an expiration date for the warrants.
What is the purpose of this warrant exercise agreement?
The filing states the agreement is for warrants exercisable for ordinary shares at a specific price, implying a mechanism for capital raising or share issuance.
Has Silexion Therapeutics Corp. received any funds from warrant exercises yet?
The filing does not provide information on whether funds have been received from warrant exercises.
What are the implications of this warrant exercise for existing shareholders?
The exercise of warrants could lead to dilution of existing shareholders' equity if new shares are issued.
Filing Stats: 847 words · 3 min read · ~3 pages · Grade level 15.1 · Accepted 2024-12-16 06:01:26
Key Financial Figures
- $0.0009 — registered Ordinary Shares, par value $0.0009 per share SLXN The Nasdaq Stock Mar
- $103.50 — Ordinary Shares at an exercise price of $103.50 per share SLXNW The Nasdaq Stock Ma
- $1.00 — Company's ordinary shares was at least $1.00 per share. Accordingly, the Company has
Filing Documents
- zk2432463.htm (8-K) — 50KB
- 0001178913-24-003984.txt ( ) — 228KB
- slxn-20241216.xsd (EX-101.SCH) — 5KB
- slxn-20241216_def.xml (EX-101.DEF) — 18KB
- slxn-20241216_lab.xml (EX-101.LAB) — 27KB
- slxn-20241216_pre.xml (EX-101.PRE) — 20KB
- zk2432463_htm.xml (XML) — 6KB
01
Item 8.01 Other Events. Remedy of Nasdaq Minimum Bid Price Compliance Deficiency On December 13, 2024, Silexion Therapeutics Corp (the " Company ") received a letter (the " Price Remedy Letter ") from the Listing Qualifications Department (the " Staff ") of The Nasdaq Stock Market LLC (" Nasdaq ") notifying the Company that the Staff has determined that for the preceding 10 consecutive business days, from November 29, 2024 to December 12, 2024, the closing bid price for the Company's ordinary shares was at least $1.00 per share. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1), and the Staff has indicated that the Company's Minimum Bid Price Deficiency (as described in the following paragraph) has been remedied. The Price Remedy Letter serves as confirmation as to the Company's remedy of a deficiency as to which the Company had received notice from the Staff of Nasdaq on October 29, 2024. As previously reported, on that date, the Company had received a letter from the Staff notifying the Company that it had failed to comply with the $1.00 per share minimum bid price requirement of Nasdaq Listing Rule 5450(a)(1) for the 30 consecutive business days preceding the letter (the " Minimum Bid Price Deficiency "). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was given 180 calendar days, or until April 28, 2025, to remedy the Minimum Bid Price Deficiency. Remedy of Nasdaq Audit Committee Compliance Deficiency On December 10, 2024, the Company received a formal notification from the Staff of Nasdaq (the " Audit Committee Remedy Letter ") confirming that the Company has regained compliance with the audit committee requirements for continued listing under Nasdaq Listing Rule 5605(c)(2), due to the appointment of Professor Amnon Peled to the Company's board of directors and audit committee on December 10, 2024. Accordingly, the Staff has indicated that the Company's Audit Committee Deficiency (as described in the fo